Acquired in 2000, Ashfield Healthcare marked our entry into the contract sales market in the UK and Ireland.
Ashfield expanded their UK contract sales (CSO) with the acquisition of Ventiv Health.
The acquisition of In2Focus and subsequent integration of Ashfield and In2Focus created Ashfield In2Focus, the UK and Ireland’s No.1 Contract Sales Organisation.
Acquired in 2007, Alliance Healthcare was a complimentary acquisition of medical call centre capabilities to strengthen US footprint and increase organic growth.
Move into contract packaging
In 2007, UDG Healthcare made its first move into the contract packaging industry with the acquisition of packaging plants in Belgium (Budelpack International) and the Netherlands (Pharma Logistics Investments BV).
Finally in 2007, the acquisition of Procon in the UK meant we entered into the growing healthcare events market.
2008 saw the acquisition of Sharp Corporation, with its state-of-the-art packaging facilities, in the US.
Pharma leadership and sales training services strengthened Ashfield’s CSO offering.
Ashfield’s Meetings & Events capability could now serve the US and the UK healthcare markets with the acquisition of Universal.
In 2010, we entered the global healthcare communications market with the acquisition of InforMed.
The acquisition of WorldEvents in 2010 made us the world’s No.1 specialist provider of international healthcare meetings and events.
Through the acquisition of Pharmexx, we added true international reach and depth to our contract sales capabilities through our expansion into 8 new countries.
The acquisition of Bilcare in the US and the UK added clinical trial and supply chain packaging expertise to our packaging portfolio.
In 2012, we moved our listing from the Irish Stock Exchange to the London Stock Exchange entering as a FTSE 250 organisation.
Watermeadow, Drug Safety Alliance and Synopia
Our final three acquisitions of 2012 were WaterMeadow Medical, Drug Safety Alliance and Synopia RX.
Launch of UDG Healthcare
In 2013, we changed our name from United Drug to UDG Healthcare plc.
Medical Communications Group
The acquisition of Medical Communications Group (MCG), a Canadian based commercial services provider strengthened our offering in Canada.
This Spanish CSO depended Ashfield’s commercial presence in Europe.
KnowledgePoint360 is our largest acquisition to date, making Ashfield a global market leader in healthcare communications.
Galliard and Nyxeon
The acquisition of Galliard and Nyxeon in 2014, diversified our healthcare communications portfolio to include scientific PR.
Disposal of UniDrug Distribution Group
We also sold our 50% share in UniDrug Distribution Group.
We formalised our joint venture with CMIC in 2015, creating CMIC Ashfield, a contract sales solution in Japan.
Sharp US Facility Expansion
We acquired a new site and invested in expanding our Sharp US facility.
Disposal of United Drug
In 2016, we completed the sale of the United Drug Supply Chain businesses and MASTA to McKesson, the culmination of 15 years of strategic development by the Group.
In 2016, we acquired Pegasus, one of the most successful integrated healthcare communications consultancies in the UK.
The acquisition of STEM Marketing was our first move into the Advisory space. STEM are the leading global provider of commercial, marketing and medical audits to pharmaceutical companies.
We acquired Sellxpert, a German and Swiss contract sales outsourcing business, based in Speyer, Germany and Basel, Switzerland, cementing our footprint in the DACH region.
The acquisition of Vynamic, a US-based healthcare industry management consultancy, further strengthened and expanded our Advisory offering.
We acquired Cambridge Biomarketing, a full-service advertising and communications agency focused on orphan diseases and specialty markets.
Our final acquisition of 2017 was the acquisition of MicroMass Communications, a US-based healthcare communications agency specialising in behavioural change
The acquisition of SmartAnalyst, a New York-based strategic commercialisation consulting and analytics business, focused on the pharmaceutical and biotech sector.
We acquired Create NYC, a New York-based disruptive creative communications agency offering the tactical execution of sales and marketing materials for its international pharmaceutical clients.
Sale of Aquilant
We announced the sale of our Aquilant division to H2 Equity Partners, a European private equity firm.